

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 17 OCTOBER 2019

The board of directors (the “**Board**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) is pleased to announce that at the special general meeting of the Company (“**SGM**”) held on 17 October 2019, the ordinary resolution as set out in the notice of SGM dated 16 September 2019 (the “**SGM Notice**”) was duly passed by the independent shareholders of the Company (“**Independent Shareholders**”) by way of poll.

Reference is made to the circular dated 16 September 2019 (the “**Circular**”) issued by the Company and the SGM Notice attached hereto. Capitalized terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

The SGM was held on 17 October 2019 to consider the ordinary resolution as set out in the SGM Notice regarding the Proposed Amendments.

As stated in the Circular, Innovative and its associates, a connected person of the Company within the meaning of the Listing Rules, shall be required to abstain from voting at the SGM. As at the date of the SGM, the total number of Shares in issue was 2,390,000,000. Innovative and its associates are holding in aggregate 189,920,000 Shares, representing approximately 7.95% of the issued share capital of the Company, have abstained from voting on the ordinary resolution proposed at the SGM. Accordingly, the total number of Shares entitling the Independent Shareholders to attend and vote for or against on the resolution at the SGM was 2,200,080,000 Shares, representing approximately 92.05% of the total number of Shares in issue as at the time of the SGM. There was no Shareholder who was entitled to attend and vote only against the resolution at the SGM.

The Company is pleased to announce the poll results in respect of the resolution proposed at the SGM as follow:

ORDINARY RESOLUTION		Number of Votes (%) (Note)	
		For	Against
1.	To approve the Proposed Amendments and authorize the Directors to do all such acts and things (including, without limitation, signing, executing (under hand or under seal)) to give effect to the Proposed Amendments.	444,410,100 (100%)	0 (0%)

Note: The number of votes and percentage of the voting are based on the total number of Shares held by the Independent Shareholders who voted at the SGM in person, by authorized corporate representative(s) or by proxies.

As more than 50% of the votes were cast in favour of the above resolution, the above resolution was duly passed as an ordinary resolution of the Company.

The branch share registrar and transfer office of the Company in Hong Kong, Tricor Tengis Limited, acted as scrutineer for the vote-taking at the SGM.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 17 October 2019

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen, Mr. Liu Kwok Wah and Mr. Lu Zhiqiang, and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

* *For identification purpose only*